Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep372 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

This study compared the impact of TGC beginning during surgery versus after surgery on postoperative adverse events in individuals undergoing heart surgery

Bharti B B , Sinha Ajay Kumar

Introduction: During the perioperative period, surgical operations put patients under a great deal of physical stress. The immune system produces cytokines and other immune mediators in response to this threat. Recent studies have shown that using insulin to regulate blood glucose can reduce systemic inflammation.Objective: The objective of this research was examined how postoperative intensive insulin treatment (IIT) affects the inflammatory response in...

ea0090ep769 | Pituitary and Neuroendocrinology | ECE2023

MRI assessment of typical pituitary gland size and shape: Age and gender associated changes

Shankar Anand , Bharti B B , Sinha Ajay Kumar , Kumar Subhash

Background: For a thorough evaluation of the pituitary gland, it is important to understand its typical structure, including the physiological differences in size and form across age groups in both males and females.Objectives: To use magnetic resonance images to examine the size, shape, and average normal volume of the normal pituitary gland at various age groups in both genders (MRI).Material and methods: 200 individuals who unde...

ea0020p386 | Diabetes and Cardiovascular | ECE2009

NovoMix30® reduces hypoglycemic events with favorable weight change in poorly controlled type 2 diabetes patients: results from Indian cohort of IMPROVE Study

Kalra Sanjay , Unnikrishnan AG , Kumar Ajay , Moharana Ashok , Prusty Vinay , Baruah Manash

Objective: IMPROVE study was designed to assess the safety and effectiveness of NovoMix30® in type 2 diabetes subjects under normal clinical practice conditions.Methods: This large multi-national, open label, prospective, 6 month long observational study captured data for above 50 000 patients started on NovoMix30® with/without oral anti-diabetic drugs (OADs)/other insulin. This paper analyses safety data of 17 995 patient...